<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326339</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-006</org_study_id>
    <nct_id>NCT00326339</nct_id>
  </id_info>
  <brief_title>Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending
      dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and
      150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12
      months and who have been receiving a weekly methotrexate (MTX) dose for a minimum of 6 months
      will be enrolled into the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the preliminary efficacy of up to three
      different dosage regimens of R788 as determined by ACR 20 responder rates at 12 weeks The
      secondary objectives of this study are to assess the safety of up to three different dosage
      regimens of R788 as determined by ACR 20 responder rates at 12 weeks, and to assess the
      general clinical and laboratory safety evaluations throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Efficacy parameter is ACR20 response rate at 3 months post dosing.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR 20/50 responses over time</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS) at baseline and endpoint</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes (SDs) from baseline in Swollen Joint Count (28 joint count)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes (SDs) from baseline in Tender Joint Count (28 joint count)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes (SDs) from baseline in Physician global assessment of disease activity by visual analog scale (VAS)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes (SDs) from baseline in Patient global assessment of disease activity by VAS</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes (SDs) from baseline in Patient assessment of pain by VAS</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes (SDs) from baseline in HAQ-DI</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes (SDs) from baseline in CRP</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency and severity of Liver Function Test abnormalities, especially ALT and alkaline phosphatase</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency and severity of hematopoietic cytopenias, principally effects on neutrophil, erythrocyte, and lymphocyte counts</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency and severity of clinically significant adverse events, especially skin rash, postural dizziness, and alterations in blood pressure and other relevant clinical outcomes</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R788 50 mg PO bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R788 100 mg PO bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R788 150 mg PO bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo PO bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R788</intervention_name>
    <description>R788 50 mg, 100 mg, or 150 mg PO bid</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>tamatinib fosdium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo PO bid</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must give written informed consent by signing an IRB-approved Informed
             Consent Form (ICF) prior to admission to this study.

          2. Males and females, 18 to 75 years of age, with active RA for at least 12 months
             (functional class I-III, e.g., not bed or wheelchair-bound) who have been receiving
             weekly doses of methotrexate (10-25 mg/week) for a minimum of 180 days, and who have
             been receiving a stable MTX dose of at least 15 mg without any change in route or
             change in folic acid supplementation for at least 30 days.

             Active RA is defined as the presence of (a)6 swollen joints (28 joint count); AND (b)6
             tender joints (28 joint count); AND (c) CRP level &gt; ULN for the central reference
             laboratory.

             Patient may receive up to 10 mg per day of oral prednisone or steroid equivalent,
             NSAID therapy, hydroxychloroquine, chloroquine, minocycline, sulfasalazine, and
             doxycycline. The dose(s) must have been stable for at least 30 days and must not be
             changed during the washout, screening and treatment periods, unless dictated by
             tolerability requirements.

          3. Females of childbearing potential must be fully informed of the potential for
             methotrexate and R788 to adversely affect the fetus and must agree to use adequate (2
             methods) contraception during the study. These patients must not be lactating and must
             have a negative urine pregnancy test at the time of randomization and at each
             laboratory determination.

          4. The patient is in otherwise good health as determined by the Investigator on the basis
             of medical history, physical examination, and laboratory screening tests during the
             screening period, including the absence of clinically significant findings, such as
             HIV, HBV or HCV, interstitial pneumonitis or active pulmonary infection, on chest
             X-ray taken within 6 months prior to screening and a negative TB skin test, or
             abnormal liver function defined as known ALT &gt;1.2xULN within the past 90 days.

          5. In the investigator's opinion, the patient has the ability to understand the nature of
             the study and any hazards of participation, and to communicate satisfactorily with the
             investigator and to participate in, and to comply with, the requirements of the entire
             protocol.

        Exclusion Criteria:

          1. The patient has a history of, or a concurrent, clinically significant illness, medical
             condition (other than arthritis) or laboratory abnormality that, in the Investigator's
             opinion, could affect the conduct of the study (these will be included in an exclusion
             log).

          2. The patient has a history of substance abuse, drug addiction or alcoholism.

          3. The patient is unable to abstain from alcohol during the study.

          4. The patient has a recent (past 5 years) history of, or treatment for, a malignancy
             other than basal skin cancer.

          5. The patient has received any investigational medication within 30 days prior to
             admission to the study.

          6. Any patient who has received any of the following treatments must abide by the
             indicated washout period:

               1. oral or injectable gold, azathioprine, penicillamine, anakinra require a 30 day
                  washout period prior to Day 1 dosing

               2. cyclosporine, abatacept, etanercept, infliximab or adalimumab require a 60 day
                  washout period prior to Day 1 dosing

               3. leflunomide requires a 60 day washout period prior to screening, unless the
                  patient has undergone cholestyramine washout at least 30 days prior to Day 1
                  dosing

               4. cyclophosphamide requires a 180 day washout period prior to Day 1 dosing

               5. Rituxan requires a 180 day washout period and normal CD19 count prior to Day 1
                  dosing

               6. parenteral or intra-articular corticosteroids require a 30 day washout period
                  prior to Day 1 dosing

          7. Patients with the following laboratory abnormalities: ALT &gt; 1.2X ULN, creatinine &gt;
             ULN, a neutrophil count &lt; 2,500/mm3 or lymphocyte count &lt; 800/mm3, Hgb &lt; 10 g/dL,
             platelet count &lt; 125,000/mm3 are excluded.

          8. Patients should not use CYP3A4 inhibitors from within 3 days of randomization until
             the end of study. R406 is metabolized by CYP3A4, and ketoconazole increases the R406
             AUC of a dose of R788 by approximately 2 fold.

          9. Patients should not use CYP3A4 inducers from within 3 days of randomization until the
             end of the study. Although glucocorticoids are inducers, a stable dose of no more than
             10 mg/day is allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliott Grossbard, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Rigel Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Weinblatt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur Kavanaugh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Arthritis Center Medical Group</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DMI research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Treatment Center</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research of Florida, Inc.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research of Florida</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Arthritis and Rheumatic Diseas</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coeur d'Alene Arthritis Clinical Trials</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814-2644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MMG Clinical Research</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phase III Clinical Research</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Arthritis Research Center</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westroad Medical Group</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Arthritis &amp; Allergy Care Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Division</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology Associates</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Ctr. for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading LLP</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Rheumatology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Rheumatology Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Arth. &amp; Rheum. Disease, PC</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica para el Diagnostico y Tratamiento de las Enfermedades Reumaticas, S.C.</name>
      <address>
        <city>Ciudad Mexico</city>
        <state>DF</state>
        <zip>06700,</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arke Estudios Clinicos, S.A. de C.V.</name>
      <address>
        <city>Ciudad Mexico</city>
        <state>DF</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Mexico</name>
      <address>
        <city>Ciudad Mexico</city>
        <state>DF</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional &quot;1° de Octubre&quot;, ISSSTE</name>
      <address>
        <city>Ciudad Mexico</city>
        <state>DF</state>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico DALINDE</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Aranda de la Parra</name>
      <address>
        <city>Leon</city>
        <state>GT</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara &quot;Fray Antonio Alcalde&quot;</name>
      <address>
        <city>Guadalajara</city>
        <state>JA</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara &quot;Dr. Juan I. Menchaca&quot;</name>
      <address>
        <city>Guadalajara</city>
        <state>JA</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico del Instituto de Seguridad Social del Estado de Mexico y Municipios (CMISSEMYM)</name>
      <address>
        <city>Metepec</city>
        <state>MX</state>
        <zip>52170</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facultad de Medicina y Hospital Universitario &quot;Dr. Jose E. Gonzalez&quot; de la Universidad Autonoma de Nuevo Leon</name>
      <address>
        <city>Monterrey</city>
        <state>NL</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</name>
      <address>
        <city>San Luis Potosi</city>
        <state>SL</state>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2006</study_first_submitted>
  <study_first_submitted_qc>May 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2006</study_first_posted>
  <last_update_submitted>April 16, 2009</last_update_submitted>
  <last_update_submitted_qc>April 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Elliott Grossbard/SVP Medical Development</name_title>
    <organization>Rigel Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>R935788</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Syk Kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

